|By Marketwired .||
|March 25, 2014 07:30 AM EDT||
DEERFIELD, IL -- (Marketwired) -- 03/25/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that Timothy P. Walbert, its chairman, president and chief executive officer, will present at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 3:30 p.m. Eastern Time in New York, NY. Mr. Walbert will provide an overview of Horizon and its corporate activities.
The presentation will be webcast live and may be accessed by visiting Horizon's website at
http://ir.horizon-pharma.com. A replay of the webcast will be available on Horizon's website for 10 business days.
About Horizon Pharma
Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS®, VIMOVO® and RAYOS®/LODOTRA®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.
Additional Information and Where to Find It
In connection with a proposed transaction with Vidara Therapeutics International Ltd., Horizon and Vidara will be filing documents with the SEC, including the filing by Horizon of a preliminary and definitive proxy statement/prospectus relating to the proposed transaction and the filing by Vidara of a registration statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Horizon stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HORIZON, VIDARA AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, by directing a request to Horizon's Investor Relations department at Horizon Pharma, Inc., Attention: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015 or to Horizon's Investor Relations department at 224-383-3000 or by email to [email protected]. Investors and security holders may obtain free copies of the documents filed with the SEC on Horizon's website at www.horizonpharma.com under the heading "Investors" and then under the heading "SEC Filings."
Horizon and its directors and executive officers and Vidara and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Horizon in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of Horizon is also included in Horizon's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 13, 2014. These documents are available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Horizon as described above.
This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Jul. 7, 2015 02:15 PM EDT Reads: 2,427
To many people, IoT is a buzzword whose value is not understood. Many people think IoT is all about wearables and home automation. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed some incredible game-changing use cases and how they are transforming industries like agriculture, manufacturing, health care, and smart cities. He will discuss cool technologies like smart dust, robotics, smart labels, and much more. Prepare...
Jul. 7, 2015 02:15 PM EDT Reads: 2,131
"We have an new division call the Cloud Monetization Division, based on our platform Powua, which empowers enterprises and organizations to take the journey to cloud monetization and to make it a reality," explained Ian Khan, Manager, Innovation & Marketing at Solgenia, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 7, 2015 02:10 PM EDT Reads: 126
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides private all-in-one social intranets allowing workers to securely collaborate from anywhere in the world and from any device. Social, mobile, and easy to use. MangoApps has been named a "Market Leader" by Ovum Research and a "Cool Vendor" by Gartner. 20,000+ business custome...
Jul. 7, 2015 02:00 PM EDT Reads: 2,149
Jul. 7, 2015 02:00 PM EDT Reads: 2,621
Jul. 7, 2015 01:45 PM EDT Reads: 2,619
Jul. 7, 2015 01:45 PM EDT Reads: 2,434
Jul. 7, 2015 01:30 PM EDT Reads: 2,721
Jul. 7, 2015 01:30 PM EDT Reads: 2,278
Jul. 7, 2015 01:15 PM EDT Reads: 1,445
Jul. 7, 2015 01:00 PM EDT Reads: 2,220
Jul. 7, 2015 01:00 PM EDT Reads: 3,116
Jul. 7, 2015 01:00 PM EDT Reads: 1,786
Jul. 7, 2015 12:45 PM EDT Reads: 1,672
Jul. 7, 2015 12:45 PM EDT Reads: 1,898